Company intelligence / Profile preview
Omniose
St. Louis, Missouri, United Statesomniose.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Omniose has demonstrated the ability to generate high-quality bioconjugate vaccines using its proprietary platform. The company has received significant grant funding ($11.8M from NIAID) for vaccine development against multiple bacterial pathogens and recently entered an exclusive collaboration with AstraZeneca for up to three years targeting new bacterial vaccine candidates. No published clinical results yet.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Polysaccharide conjugate vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
AstraZenecaNational Institute of Allergy and Infectious Diseases (NIAID)
Beyond the preview
Go deeper on Omniose.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omniose.